2 studies on Pd 1 mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study provides compelling evidence that Thymalfasin can significantly augment the effectiveness of immune checkpoint inhibitors in patients with advanced NSCLC, leading to better response rates and prolonged surv…
This ambitious Phase II trial represents a significant effort to push the boundaries of locally advanced NSCLC treatment by integrating multiple advanced therapeutic strategies. If successful, this regimen could offer…